Developer docs
API playgroundTry for free, no card

Search company profiles

Alysophil

Full company profile

uuid00eohja

Namestring
Alysophil
Legal namestring
ALYSOPHIL SAS
Websiteurl
alysophil.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Alysophil is a French private deeptech company with 11-50 employees that develops AI-enabled continuous-flow manufacturing systems for chemical and pharmaceutical companies. Its technology stack combines continuous-flow reactors, AI-driven process optimization and autonomous control, digital twins, and in-line NMR, with deployment centered on localized, just-in-time production of APIs and specialty chemicals. The company also uses molecule generation to address customer-specific synthesis requirements.

Commercial offerings include AlChemAI, a chemistry platform for structure-property modeling, constrained de novo molecule generation, anomaly detection, and process optimization; ChemPocket, a 25m² micro-factory claimed to produce up to 3,000 tonnes annually; and AlchemDrive, an edge-AI controller for industrial production equipment. Alysophil also participates in PIPAc, an autonomous continuous API-manufacturing system integrating flow chemistry, in-line benchtop NMR, digital twins, and AI control that was validated on fentanyl and propofol workflows.

Alysophil's stated revenue mechanics combine ChemPocket sale or lease and Chemical-as-a-Service deployment, AI-enabled molecule-generation and process-optimization services, and licensing or co-commercialization through PIPAc. Its go-to-market relies on direct enterprise engagement with large pharmaceutical and industrial customers, supplemented by strategic partnerships and consortium-led demonstrations; public list prices and contract values are not disclosed. Pharmaceutical and life-sciences applications are the primary served segment, with additional activity in defense, aerospace, cosmetics, aromas and fragrances, construction, electronics, and advanced manufacturing.

Short descriptiontext

Alysophil is a French deeptech company combining AI, continuous-flow chemistry, real-time analytics, and compact micro-factories to enable on-demand molecule generation and manufacturing for pharmaceutical, chemical, defense, and advanced-materials companies globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIllkirch-graffenstaden, France
HQ citystring
Illkirch-graffenstaden
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous flow chemistry, micro-factory manufacturing, AI molecule generation, pharmaceutical API production, autonomous process control
Industry4 codes
PRIMARYHLAGAHAK
Flow Chemistry & Process Intensification Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
SECONDARYHDAAAHAJ
Process Mining, Predictive Process Analytics & Automation Intelligence
NAICS code3 codes
  • Chemical Manufacturing325
  • Pharmaceutical and Medicine Manufacturing32541
  • All Other Chemical Product and Preparation Manufacturing32599
SIC code3 codes
  • Industrial Organic Chemicals2860
  • Chemicals & Allied Products2800
  • Miscellaneous Chemical Products2890
Product category
Specialty Chemical Manufacturing Technology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Micro-factory (ChemPocket) sales / Chemical-as-a-Service
TypeHardware Sales
Description

Sale or lease of ChemPocket micro-factory units to industrial customers, enabling localized continuous flow chemical production. Positioned as 'Chemical as a Service' model, implying a managed service or unit-based pricing structure for on-site chemical manufacturing.

alysophil.com
2AI-powered molecule generation and process optimization services
TypeProfessional Services
Description

Generation of novel molecules (1M+ library) and AI-driven process optimization services for customer-specific synthesis challenges across pharmaceuticals, cosmetics, flavors, defense, and specialty chemicals.

alysophil.com
3Licensing / co-development of PIPAc platform technology
TypeLicensing Royalties
Description

PIPAc consortium platform — co-developed autonomous manufacturing technology — is brought to market through licensing or co-commercialization arrangements with consortium partners (Bruker, NovAliX, De Dietrich Process Systems) for pharmaceutical API production.

news-medical.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1AlChemAI
Description

AI platform for chemistry applications including structure-property relationships, molecule generation under constraints, process optimization, anomaly detection, and production control.

alysophil.com
+3 more records
Core offering1 text field

Alysophil develops AI-augmented continuous flow chemistry solutions delivered through its ChemPocket modular micro-factory (25m² footprint producing up to 3,000 tonnes/year). The company sells hardware units (ChemPocket), AI software platforms (AlChemAI for molecule generation and process optimization, AlchemDrive for edge AI process control), and contract research services to pharmaceutical, specialty chemical, defense, and cosmetics manufacturers seeking localized, on-demand chemical production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 3,000 tonnes/year production capacity from a 25m² micro-factory unit
+2 more records
Product overview1 text field

Alysophil operates as a deeptech company offering intelligent flow chemistry solutions augmented with AI. The core product portfolio consists of AlChemAI (an AI platform for molecule generation, structure-property analysis, and process optimization), ChemPocket (a compact 25m² micro-factory for continuous flow chemical production up to 3,000 tonnes/year), and AlchemDrive (Edge AI for autonomous industrial control). These products are interconnected: AlChemAI drives the intelligent control of ChemPocket micro-factories and the PIPAc consortium-developed pharmaceutical manufacturing platform. The company targets pharmaceutical, defense, aerospace, fragrance, cosmetics, and construction sectors with solutions for supply chain resilience and on-demand manufacturing.

Product and service4 records
1ChemPocket Micro-Factory
CategoryMicro-factory hardware
Description

A modular continuous flow chemistry micro-factory in a container-sized 25m² footprint capable of producing up to 3,000 tonnes per year. Sold or leased to industrial customers for on-site, on-demand production of specialty chemicals and APIs, enabling just-in-time manufacturing and relocalization of chemical activities.

2AlChemAI
CategoryAI software platform
Description

AI-powered platform providing solutions across the chemical value chain (research, modeling, production) including structure-property relationships (toxicity prediction, odor anticipation), de novo molecule generation under constraints, manufacturing process optimization, anomaly detection, and autonomous flow production control. Backed by a proprietary library of 1 million never-before-synthesized molecules generated by deep neural networks trained since 2017.

3AlchemDrive
CategoryEdge AI software module
Description

Edge AI solution for autonomous industrial piloting of polymer and material production equipment, enabling real-time adaptive control without cloud dependency.

4PIPAc Platform
CategoryAutonomous pharmaceutical manufacturing platform
Description

AI-driven autonomous continuous manufacturing platform integrating continuous flow chemistry, in-line benchtop NMR spectroscopy, digital twin technology, and AI control systems for pharmaceutical API production. Co-developed by the PIPAc consortium (Alysophil, Bruker, NovAliX, De Dietrich Process Systems). Validated on fentanyl and propofol workflows with real-time monitoring and adaptive optimization.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1PIPAc Consortium (Bruker, NovAliX, De Dietrich Process Systems)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-08-06
Description

The PIPAc consortium — comprising Bruker (NMR/in-line analytics), NovAliX (pharmaceutical manufacturing), De Dietrich Process Systems (process equipment), and Alysophil (AI/flow chemistry) — successfully validated an AI-driven autonomous continuous manufacturing platform for pharmaceutical APIs. The platform integrates continuous flow chemistry, in-line NMR spectroscopy, digital twin technology, and AI control systems. Validated on fentanyl and propofol workflows demonstrating real-time monitoring and adaptive optimization. The consortium brings Pharma 4.0-aligned, just-in-time pharmaceutical manufacturing to market.

news-medical.net
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

TotalEnergies renewed its collaboration with Alysophil and Quandela to continue applying AI and quantum computing to the design of innovative materials. The partnership focuses on developing advanced materials using quantum computing-enhanced neural networks for polymer design.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

MBDA (defense and aerospace company) renewed its collaboration with Alysophil and Quandela for AI and quantum computing applications in innovative materials design. MBDA also co-funded the CLEE project (high-energy liquid fuels in continuous flow) and the quantum computing polymer synthesis project initiated in 2022.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

Quandela and Alysophil have collaborated since 2022 (renewed 2025) on applying quantum computing and AI to polymer synthesis. The project, co-funded by MBDA, aims to develop neural networks for quantum computers to propose new polymer solutions for advanced materials markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-13
Description

De Dietrich Process Systems made a strategic equity investment in Alysophil and formed a partnership to strengthen expertise in continuous flow chemistry. De Dietrich integrates Alysophil's flow chemistry capabilities into its process equipment portfolio, serving as a key channel to industrial customers globally.

6Inria
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-10-01
Description

Inria (French National Institute for Digital Science) partnered with Alysophil and MBDA on the CLEE project, funded by the French Defense Innovation Agency (AID), for the manufacturing of High-Energy Liquid Fuels (CLEE) in continuous flow and the development of novel fuels.

alysophil.com
Strategic tierCoreTypeTechnology or Integration
Description

Seven-year partnership with NovAliX (since 2019 at Bioparc d'Illkirch). NovAliX provides pharmaceutical manufacturing expertise to the PIPAc consortium alongside Alysophil's AI and flow chemistry capabilities. Alysophil's new headquarters at Campus Ourisson follows a seven-year NovAliX partnership, suggesting deep operational integration.

Strategic tierCoreTypeTechnology or Integration
Description

Bruker provides in-line benchtop NMR spectroscopy for real-time process monitoring and quality assurance within the PIPAc autonomous manufacturing platform. Bruker's NMR technology is a core analytical component enabling closed-loop AI control of continuous flow chemical reactions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based manufacturer of flow chemistry (FlowCAT) and process safety/reaction calorimetry instruments for pharma, chemicals and battery R&D. Comparable in serving process development customers with continuous reactor and process-analytic technology.

TypeDirect peer
Description

UK-based manufacturer of continuous flow chemistry reactors and systems for pharma and fine chemicals R&D and production. Directly competes with ChemPocket as a modular flow chemistry platform, though without Alysophil's AI/edge-control layer.

TypeDirect peer
Description

German supplier of modular flow chemistry and microreactor technology (FlowPlate, Lonza-Fox) for process development and production. Direct peer in containerized, production-scale flow chemistry moving into pharma manufacturing.

TypeDirect peer
Description

Developer of flow chemistry systems (Asia, Atlas, Titan) for laboratory and process-scale chemical manufacturing. Closely comparable to Alysophil's flow chemistry micro-factory approach across pharma and specialty chemicals customers.

TypeBroad incumbent
Description

Computational chemistry and molecular simulation platform used for drug discovery and materials design. Adjacent to AlChemAI's generative molecule and property-prediction capabilities, but focused on software rather than physical flow chemistry.

TypeDirect peer
Description

Dutch provider of continuous flow reactors (Protrix, KiloFlow, Plantrix) from lab to production scale. Comparable modular flow-chemistry play targeting the same pharma and fine-chemicals use cases as ChemPocket.

7Asymchem (Snapdragon Chemistry)
TypeEmerging player
Description

CDMO with a strong continuous flow chemistry and automation offering for API development and manufacturing. Comparable as a commercial-scale flow-chemistry player in pharma, partially overlapping Alysophil's PIPAc use cases.

TypeEmerging player
Description

Generative AI platform for protein and molecule design. Comparable to AlChemAI's generative molecule capabilities and use of AI for designing novel high-value molecules, though Cradle focuses on biologics rather than flow-chemistry manufacturing.

TypeBroad incumbent
Description

AI platform for materials and chemicals R&D, including formulation and process optimization. Comparable to the AI-driven process optimization layer of Alysophil's stack, applied to specialty chemicals and materials customers.

TypeBroad incumbent
Description

Division of Corning offering industrial-scale continuous flow reactors (G1, G3, G4) widely adopted in pharma and specialty chemicals. Broad incumbent with overlapping flow chemistry capability, but no integrated AI/digital-twin stack comparable to AlChemAI.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alysophil

Specialty Chemical Manufacturing Technologyalysophil.com

Alysophil is a French deeptech company combining AI, continuous-flow chemistry, real-time analytics, and compact micro-factories to enable on-demand molecule generation and manufacturing for pharmaceutical, chemical, defense, and advanced-materials companies globally.

What Alysophil does

Alysophil is a French private deeptech company with 11-50 employees that develops AI-enabled continuous-flow manufacturing systems for chemical and pharmaceutical companies. Its technology stack combines continuous-flow reactors, AI-driven process optimization and autonomous control, digital twins, and in-line NMR, with deployment centered on localized, just-in-time production of APIs and specialty chemicals. The company also uses molecule generation to address customer-specific synthesis requirements.

Commercial offerings include AlChemAI, a chemistry platform for structure-property modeling, constrained de novo molecule generation, anomaly detection, and process optimization; ChemPocket, a 25m² micro-factory claimed to produce up to 3,000 tonnes annually; and AlchemDrive, an edge-AI controller for industrial production equipment. Alysophil also participates in PIPAc, an autonomous continuous API-manufacturing system integrating flow chemistry, in-line benchtop NMR, digital twins, and AI control that was validated on fentanyl and propofol workflows.

Alysophil's stated revenue mechanics combine ChemPocket sale or lease and Chemical-as-a-Service deployment, AI-enabled molecule-generation and process-optimization services, and licensing or co-commercialization through PIPAc. Its go-to-market relies on direct enterprise engagement with large pharmaceutical and industrial customers, supplemented by strategic partnerships and consortium-led demonstrations; public list prices and contract values are not disclosed. Pharmaceutical and life-sciences applications are the primary served segment, with additional activity in defense, aerospace, cosmetics, aromas and fragrances, construction, electronics, and advanced manufacturing.

Alysophil firmographics

Firmographics
Name
Alysophil
Legal name
ALYSOPHIL SAS
Website
https://alysophil.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Alysophil is a French deeptech company combining AI, continuous-flow chemistry, real-time analytics, and compact micro-factories to enable on-demand molecule generation and manufacturing for pharmaceutical, chemical, defense, and advanced-materials companies globally.
Ownership category
akta.pro rank

Alysophil industry classification

Industry
Product category
Specialty Chemical Manufacturing Technology
NAICS
Chemical Manufacturing (325), Pharmaceutical and Medicine Manufacturing (32541), All Other Chemical Product and Preparation Manufacturing (32599)
SIC
Industrial Organic Chemicals (2860), Chemicals & Allied Products (2800), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAGAHAK
Flow Chemistry & Process Intensification Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYBPAEAHAF
AI/ML Engineering & Model Development Services
SECONDARYHDAAAHAJ
Process Mining, Predictive Process Analytics & Automation Intelligence

Keywords

  • Continuous flow chemistry
  • Micro-factory manufacturing
  • AI molecule generation
  • Pharmaceutical API production
  • Autonomous process control

Where Alysophil is headquartered

Location

Headquarters

HQ city
Illkirch-graffenstaden
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Alysophil business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Micro-factory (ChemPocket) sales / Chemical-as-a-Service: Sale or lease of ChemPocket micro-factory units to industrial customers, enabling localized continuous flow chemical production. Positioned as 'Chemical as a Service' model, implying a managed service or unit-based pricing structure for on-site chemical manufacturing.
  2. AI-powered molecule generation and process optimization services: Generation of novel molecules (1M+ library) and AI-driven process optimization services for customer-specific synthesis challenges across pharmaceuticals, cosmetics, flavors, defense, and specialty chemicals.
  3. Licensing / co-development of PIPAc platform technology: PIPAc consortium platform — co-developed autonomous manufacturing technology — is brought to market through licensing or co-commercialization arrangements with consortium partners (Bruker, NovAliX, De Dietrich Process Systems) for pharmaceutical API production.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Alysophil product offering

Product offering

Core offering

Alysophil develops AI-augmented continuous flow chemistry solutions delivered through its ChemPocket modular micro-factory (25m² footprint producing up to 3,000 tonnes/year). The company sells hardware units (ChemPocket), AI software platforms (AlChemAI for molecule generation and process optimization, AlchemDrive for edge AI process control), and contract research services to pharmaceutical, specialty chemical, defense, and cosmetics manufacturers seeking localized, on-demand chemical production.

Product overview

Alysophil operates as a deeptech company offering intelligent flow chemistry solutions augmented with AI. The core product portfolio consists of AlChemAI (an AI platform for molecule generation, structure-property analysis, and process optimization), ChemPocket (a compact 25m² micro-factory for continuous flow chemical production up to 3,000 tonnes/year), and AlchemDrive (Edge AI for autonomous industrial control). These products are interconnected: AlChemAI drives the intelligent control of ChemPocket micro-factories and the PIPAc consortium-developed pharmaceutical manufacturing platform. The company targets pharmaceutical, defense, aerospace, fragrance, cosmetics, and construction sectors with solutions for supply chain resilience and on-demand manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • AlChemAI: AI platform for chemistry applications including structure-property relationships, molecule generation under constraints, process optimization, anomaly detection, and production control.
  • ChemPocket
  • AlchemDrive
  • PIPAc

Products and services

  • ChemPocket Micro-Factory A modular continuous flow chemistry micro-factory in a container-sized 25m² footprint capable of producing up to 3,000 tonnes per year. Sold or leased to industrial customers for on-site, on-demand production of specialty chemicals and APIs, enabling just-in-time manufacturing and relocalization of chemical activities.
  • AlChemAI AI-powered platform providing solutions across the chemical value chain (research, modeling, production) including structure-property relationships (toxicity prediction, odor anticipation), de novo molecule generation under constraints, manufacturing process optimization, anomaly detection, and autonomous flow production control. Backed by a proprietary library of 1 million never-before-synthesized molecules generated by deep neural networks trained since 2017.
  • AlchemDrive Edge AI solution for autonomous industrial piloting of polymer and material production equipment, enabling real-time adaptive control without cloud dependency.
  • PIPAc Platform AI-driven autonomous continuous manufacturing platform integrating continuous flow chemistry, in-line benchtop NMR spectroscopy, digital twin technology, and AI control systems for pharmaceutical API production. Co-developed by the PIPAc consortium (Alysophil, Bruker, NovAliX, De Dietrich Process Systems). Validated on fentanyl and propofol workflows with real-time monitoring and adaptive optimization.

Quantifiable outcome

  • Up to 3,000 tonnes/year production capacity from a 25m² micro-factory unit
  • +2 more outcomes

Companies that use Alysophil

Customer profile

Segments7 records

Ideal customer profiles4 records

Alysophil technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Alysophil partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and major.

  • PIPAc Consortium (Bruker, NovAliX, De Dietrich Process Systems)coreStrategic or Co-development Partner · 6 August 2026The PIPAc consortium — comprising Bruker (NMR/in-line analytics), NovAliX (pharmaceutical manufacturing), De Dietrich Process Systems (process equipment), and Alysophil (AI/flow chemistry) — successfully validated an AI-driven autonomous continuous manufacturing platform for pharmaceutical APIs. The platform integrates continuous flow chemistry, in-line NMR spectroscopy, digital twin technology, and AI control systems. Validated on fentanyl and propofol workflows demonstrating real-time monitoring and adaptive optimization. The consortium brings Pharma 4.0-aligned, just-in-time pharmaceutical manufacturing to market.
  • TotalEnergiesmajorStrategic or Co-development Partner · 4 June 2025TotalEnergies renewed its collaboration with Alysophil and Quandela to continue applying AI and quantum computing to the design of innovative materials. The partnership focuses on developing advanced materials using quantum computing-enhanced neural networks for polymer design.
  • MBDAmajorStrategic or Co-development Partner · 4 June 2025MBDA (defense and aerospace company) renewed its collaboration with Alysophil and Quandela for AI and quantum computing applications in innovative materials design. MBDA also co-funded the CLEE project (high-energy liquid fuels in continuous flow) and the quantum computing polymer synthesis project initiated in 2022.
  • QuandelamajorStrategic or Co-development Partner · 4 June 2025Quandela and Alysophil have collaborated since 2022 (renewed 2025) on applying quantum computing and AI to polymer synthesis. The project, co-funded by MBDA, aims to develop neural networks for quantum computers to propose new polymer solutions for advanced materials markets.
  • De Dietrich Process SystemscoreStrategic or Co-development Partner · 13 September 2023De Dietrich Process Systems made a strategic equity investment in Alysophil and formed a partnership to strengthen expertise in continuous flow chemistry. De Dietrich integrates Alysophil's flow chemistry capabilities into its process equipment portfolio, serving as a key channel to industrial customers globally.
  • InriamajorStrategic or Co-development Partner · 1 October 2022Inria (French National Institute for Digital Science) partnered with Alysophil and MBDA on the CLEE project, funded by the French Defense Innovation Agency (AID), for the manufacturing of High-Energy Liquid Fuels (CLEE) in continuous flow and the development of novel fuels.
  • NovAliXcoreTechnology or IntegrationSeven-year partnership with NovAliX (since 2019 at Bioparc d'Illkirch). NovAliX provides pharmaceutical manufacturing expertise to the PIPAc consortium alongside Alysophil's AI and flow chemistry capabilities. Alysophil's new headquarters at Campus Ourisson follows a seven-year NovAliX partnership, suggesting deep operational integration.
  • BrukercoreTechnology or IntegrationBruker provides in-line benchtop NMR spectroscopy for real-time process monitoring and quality assurance within the PIPAc autonomous manufacturing platform. Bruker's NMR technology is a core analytical component enabling closed-loop AI control of continuous flow chemical reactions.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Alysophil competitors and assessment

Company assessment

Direct peers

  • H.E.L Group: UK-based manufacturer of flow chemistry (FlowCAT) and process safety/reaction calorimetry instruments for pharma, chemicals and battery R&D. Comparable in serving process development customers with continuous reactor and process-analytic technology.
  • Vapourtec: UK-based manufacturer of continuous flow chemistry reactors and systems for pharma and fine chemicals R&D and production. Directly competes with ChemPocket as a modular flow chemistry platform, though without Alysophil's AI/edge-control layer.
  • Ehrfeld Mikrotechnik BTS: German supplier of modular flow chemistry and microreactor technology (FlowPlate, Lonza-Fox) for process development and production. Direct peer in containerized, production-scale flow chemistry moving into pharma manufacturing.
  • Syrris: Developer of flow chemistry systems (Asia, Atlas, Titan) for laboratory and process-scale chemical manufacturing. Closely comparable to Alysophil's flow chemistry micro-factory approach across pharma and specialty chemicals customers.
  • Chemtrix: Dutch provider of continuous flow reactors (Protrix, KiloFlow, Plantrix) from lab to production scale. Comparable modular flow-chemistry play targeting the same pharma and fine-chemicals use cases as ChemPocket.

Broad incumbents

  • Schrödinger: Computational chemistry and molecular simulation platform used for drug discovery and materials design. Adjacent to AlChemAI's generative molecule and property-prediction capabilities, but focused on software rather than physical flow chemistry.
  • Citrine Informatics: AI platform for materials and chemicals R&D, including formulation and process optimization. Comparable to the AI-driven process optimization layer of Alysophil's stack, applied to specialty chemicals and materials customers.
  • Corning Advanced-Flow Reactors (AFR): Division of Corning offering industrial-scale continuous flow reactors (G1, G3, G4) widely adopted in pharma and specialty chemicals. Broad incumbent with overlapping flow chemistry capability, but no integrated AI/digital-twin stack comparable to AlChemAI.

Emerging players

  • Asymchem (Snapdragon Chemistry): CDMO with a strong continuous flow chemistry and automation offering for API development and manufacturing. Comparable as a commercial-scale flow-chemistry player in pharma, partially overlapping Alysophil's PIPAc use cases.
  • Cradle: Generative AI platform for protein and molecule design. Comparable to AlChemAI's generative molecule capabilities and use of AI for designing novel high-value molecules, though Cradle focuses on biologics rather than flow-chemistry manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Alysophil social profiles

Digital presence

Alysophil financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alysophil leadership team

Management profile

Number of profiles

Profiles1 record

Alysophil funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alysophil M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alysophil

What does Alysophil do?

Alysophil develops AI-augmented continuous flow chemistry solutions delivered through its ChemPocket modular micro-factory (25m² footprint producing up to 3,000 tonnes/year). The company sells hardware units (ChemPocket), AI software platforms (AlChemAI for molecule generation and process optimization, AlchemDrive for edge AI process control), and contract research services to pharmaceutical, specialty chemical, defense, and cosmetics manufacturers seeking localized, on-demand chemical production.

Is Alysophil a public or private company?

Alysophil is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alysophil founded?

Alysophil was founded in 2017. It employs 11 to 50 people.

Where is Alysophil based?

Alysophil is headquartered in Illkirch-graffenstaden, France, in the Europe region.

How does Alysophil make money?

Three revenue lines are on record. Micro-factory (ChemPocket) sales / Chemical-as-a-Service is the primary driver. The others are AI-powered molecule generation and process optimization services and licensing / co-development of PIPAc platform technology.

Who are Alysophil's main competitors?

Direct peers on record are H.E.L Group, Vapourtec, Ehrfeld Mikrotechnik BTS, Syrris and Chemtrix. Broad incumbents are Schrödinger, Citrine Informatics and Corning Advanced-Flow Reactors (AFR). Emerging players are Asymchem (Snapdragon Chemistry) and Cradle.

Does Alysophil have an API?

No public API is recorded for Alysophil.

What industry is Alysophil in?

Alysophil's product category is Specialty Chemical Manufacturing Technology. Its primary akta.pro industry code is HLAGAHAK, Flow Chemistry & Process Intensification Services, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 325 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals